RxDoctor Payments Data

Arturo Lopez, MD

Pulmonary Disease · San Antonio, TXNPI 1932137882

Payments from drug & device makers

$9,472in general payments, 2019–2025

Across 407 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Abiomed$775
  • Boehringer Ingelheim$738
  • AstraZeneca$675
  • United Therapeutics Corporation$404
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,39199%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,472 in reported general payments places this provider in the 70th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$209,341
Medicare patients
659
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan57$722,083
OfevNintedanib Esylate49$637,901
UptraviSelexipag34$634,466
Tyvaso DpiTreprostinil24$544,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter197$162,021
Prolastin CAlpha-1-Proteinase Inhibitor12$143,416
Ambrisentan21$43,778
Breo ElliptaFluticasone/Vilanterol28$16,891
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,766
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,045
EliquisApixaban11$6,282
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$5,905
Tadalafil50$3,628
Albuterol Sulfate HfaAlbuterol Sulfate91$2,756
Azelastine Hcl13$723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,555$1,356,54991 claims
Boehringer IngelheimOfev$738$637,90149 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,558$189,678237 claims
Grifols USA, LLCProlastin C$349$143,41612 claims
AstraZenecaBreztri Aerosphere$675$8,04511 claims
PfizerEliquis$19$6,28211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →